A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

NCT01408888 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the medications LY2189265 and sitagliptin in adults with type 2 diabetes to understand how the body processes sitagliptin.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 29 people

Who can join Ages 18–75 · all sexes

Timeline Started 2011-08 · est. completion 2012-04

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT01408888 ↗

Description as written by the study sponsor.

The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration). The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.

Treatments tested

LY2189265 also known as Dulaglutide Biologic

Administered subcutaneously
Sitagliptin Drug

Administered orally

Main thing measured	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01408888 ↗